Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial
ID Milligan, MM Gibani, R Sewell, EA Clutterbuck… - Jama, 2016 - jamanetwork.com
Importance Developing effective vaccines against Ebola virus is a global priority. Objective
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.
ZEBOV) and a modified vaccinia Ankara vector vaccine, encoding glycoproteins from Ebola
virus, Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein (MVA-BN-Filo). Design,
Setting, and Participants Single-center, randomized, placebo-controlled, observer-blind,
phase 1 trial performed in Oxford, United Kingdom, enrolling healthy 18-to 50-year-olds from …
To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.
ZEBOV) and a modified vaccinia Ankara vector vaccine, encoding glycoproteins from Ebola
virus, Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein (MVA-BN-Filo). Design,
Setting, and Participants Single-center, randomized, placebo-controlled, observer-blind,
phase 1 trial performed in Oxford, United Kingdom, enrolling healthy 18-to 50-year-olds from …
